Insider Trading Alert - HAFC, PLCE And MDSO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Dec. 5, 2014, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $85.00 to $13,664,800.00.

Highlighted Stocks Traded by Insiders:

Hanmi Financial (HAFC) - FREE Research Report

Lee Joon Hyung, who is Director at Hanmi Financial, sold 3,000 shares at $21.32 on Dec. 5, 2014. Following this transaction, the Director owned 280,697 shares meaning that the stake was reduced by 1.06% with the 3,000-share transaction.

Rho Joseph K, who is Director at Hanmi Financial, sold 9,000 shares at $21.35 on Dec. 5, 2014. Following this transaction, the Director owned 365,966 shares meaning that the stake was reduced by 2.4% with the 9,000-share transaction.

The shares most recently traded at $21.32, down $0.03, or 0.14% since the insider transaction. Historical insider transactions for Hanmi Financial go as follows:

  • 4-Week # shares bought: 8,750
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 8,750
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 8,750
  • 24-Week # shares sold: 5,000

The average volume for Hanmi Financial has been 154,000 shares per day over the past 30 days. Hanmi Financial has a market cap of $662.6 million and is part of the financial sector and banking industry. Shares are down 1.87% year-to-date as of the close of trading on Friday.

Hanmi Financial Corporation operates as the holding company for Hanmi Bank that operates as a community bank in the United States. The stock currently has a dividend yield of 1.35%. The company has a P/E ratio of 14.4. Currently, there are 5 analysts who rate Hanmi Financial a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on HAFC - FREE

TheStreet Quant Ratings rates Hanmi Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, increase in net income, growth in earnings per share and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Hanmi Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Children's Place (PLCE) - FREE Research Report

Scarpa Michael, who is Chief Operating Officer at Children's Place, sold 3,509 shares at $53.17 on Dec. 5, 2014. Following this transaction, the Chief Operating Officer owned 67,691 shares meaning that the stake was reduced by 4.93% with the 3,509-share transaction.

The shares most recently traded at $53.69, up $0.52, or 0.97% since the insider transaction. Historical insider transactions for Children's Place go as follows:

  • 4-Week # shares sold: 3,938
  • 12-Week # shares sold: 3,938
  • 24-Week # shares sold: 27,337

The average volume for Children's Place has been 392,500 shares per day over the past 30 days. Children's Place has a market cap of $1.1 billion and is part of the services sector and retail industry. Shares are down 6.46% year-to-date as of the close of trading on Friday.

The Children's Place, Inc. operates as a children's specialty apparel retailer in North America. It sells apparel, accessories, and footwear for children; and designs, contracts, manufactures, and sells merchandise under the The Children's Place, Place, and Baby Place brands. The stock currently has a dividend yield of 1%. The company has a P/E ratio of 21.3. Currently, there are 4 analysts who rate Children's Place a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PLCE - FREE

TheStreet Quant Ratings rates Children's Place as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Children's Place Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Medidata Solutions (MDSO) - FREE Research Report

Hirschfeld Steven Isaac, who is Chief Commercial Officer at Medidata Solutions, sold 22,075 shares at $42.53 on Dec. 5, 2014. Following this transaction, the Chief Commercial Officer owned 46,413 shares meaning that the stake was reduced by 32.23% with the 22,075-share transaction.

The shares most recently traded at $43.75, up $1.22, or 2.8% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 11,260
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 51,260
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 229,716

The average volume for Medidata Solutions has been 470,300 shares per day over the past 30 days. Medidata Solutions has a market cap of $2.3 billion and is part of the technology sector and computer software & services industry. Shares are down 28.32% year-to-date as of the close of trading on Friday.

Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company has a P/E ratio of 2118.0. Currently, there are 10 analysts who rate Medidata Solutions a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings rates Medidata Solutions as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Medidata Solutions Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%